We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-11.17%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$775M
AUM Growth
-$224M
Cap. Flow
-$90.9M
Cap. Flow %
-11.73%
Top 10 Hldgs %
46.3%
Holding
85
New
17
Increased
18
Reduced
18
Closed
20

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$27M
2
OSUR icon
OraSure Technologies
OSUR
+$24.4M
3
ILMN icon
Illumina
ILMN
+$21.6M
4
ACLX
Arcellx
ACLX
+$16.5M
5
HOLX
Hologic
HOLX
+$16.2M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$59.5M
2
AZN icon
AstraZeneca
AZN
+$21.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$9.58M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.53M
5
SNN icon
Smith & Nephew
SNN
+$6.99M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Financials 0.5%
3 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
51
Intuitive Surgical
ISRG
$134B
$2.35M 0.3%
+7,800
New +$2.28M
CLDX icon
52
Celldex Therapeutics
CLDX
$3.25B
$2.35M 0.3%
+69,000
New +$2.21M
VSTM icon
53
Verastem
VSTM
$577M
$2.32M 0.3%
137,042
– –
LQDA icon
54
Liquidia Corp
LQDA
$8B
$2.11M 0.27%
293,485
+62,000
+27% +$390K
CTKB icon
55
Cytek Biosciences
CTKB
$546M
$1.94M 0.25%
+180,000
New +$2.43M
TVRD
56
Tvardi Therapeutics
TVRD
$23.2M
$1.93M 0.25%
4,422
-7,445
-63% -$3.06M
PCRX icon
57
Pacira BioSciences
PCRX
$1.01B
$1.7M 0.22%
22,250
-79,350
-78% -$5.29M
PLRX icon
58
Pliant Therapeutics
PLRX
$65.6M
$1.68M 0.22%
+240,000
New +$2.45M
VRDN icon
59
Viridian Therapeutics
VRDN
$2.64B
$1.66M 0.21%
90,000
– –
NVCR icon
60
NovoCure
NVCR
$1.9B
$1.43M 0.18%
17,275
-5,000
-22% -$368K
CRSP icon
61
CRISPR Therapeutics
CRSP
$5.19B
$1.38M 0.18%
22,000
– –
DALS
62
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$972K 0.13%
100,000
-250,000
-71% -$2.41M
OLK
63
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$953K 0.12%
+53,961
New +$880K
CELC icon
64
Celcuity
CELC
$4.48B
$300K 0.04%
32,073
– –
ABBV icon
65
AbbVie
ABBV
$434B
– –
-27,500
Closed -$3.72M
ARVN icon
66
Arvinas
ARVN
$571M
– –
-11,000
Closed -$904K
AVTX icon
67
Avalo Therapeutics
AVTX
$981M
– –
-267
Closed -$1.31M
BAX icon
68
Baxter International
BAX
$14.4B
– –
-51,000
Closed -$4.38M
BCYC
69
Bicycle Therapeutics
BCYC
$294M
– –
-10,250
Closed -$624K
BEAM icon
70
Beam Therapeutics
BEAM
$2.84B
– –
-2,850
Closed -$227K
BVS icon
71
Bioventus
BVS
$1.18B
– –
-428,397
Closed -$6.21M
DYN icon
72
Dyne Therapeutics
DYN
$4.88B
– –
-338,760
Closed -$4.03M
LKFT
73
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
– –
-98,800
Closed -$5.45M
HOWL icon
74
Werewolf Therapeutics
HOWL
$19.6M
– –
-64,585
Closed -$769K
IWM icon
75
PUT
iShares Russell 2000 ETF
IWM
$83B
– –
-508,500
Closed -$113M
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Soleus Capital Management held 85 positions worth $775M, down 22% from $999M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $90.9M in Q1 2022, closing 20 positions and reducing 18 holdings. Its most notable exit was Bioventus, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 71% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in OraSure Technologies worth $20.7M.

  • Soleus Capital Management's largest Q1 2022 buy was OraSure Technologies: 3,055,193 shares worth $20.7M.
  • Soleus Capital Management added most to United Therapeutics in Q1 2022, an estimated $27M increase.
  • Soleus Capital Management's biggest Q1 2022 reduction was Lantheus, cutting an estimated $59.5M.
  • Soleus Capital Management fully exited Bioventus in Q1 2022, selling an estimated $6.21M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $775M portfolio in Q1 2022.
  • Soleus Capital Management opened 17 new positions and closed 20 in Q1 2022.
  • Soleus Capital Management's portfolio value fell 22% quarter-over-quarter to $775M.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.